clinical trial · NCT06908928
A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
Mabwell (Shanghai) Bioscience Co., Ltd.·phase1·recruiting·n = 52
Triple Negative Breast Cancerbulumtatug fuvedotinbulumtatug fuvedotin
brief summary
The goal of this clinical trial is to investigate if treatment with bulumtatug fuvedotin is effective in triple-negative breast cancer patients who have previously received treatment with an antibody-drug conjugates.
started
Aug 11, 2025
primary completion
May 1, 2027
completion
May 1, 2028
last updated
Mar 17, 2026
official title
An Open-Label, Multicenter, Phase Ib Dose Randomization Study of Bulumtatug Furvedotin (BFv; 9MW2821) in Subjects With Recurrent or Metastatic Triple-Negative Breast Cancer Previously Treated With Antibody-Drug Conjugates
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol